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Varicella zoster virus (VZV) is considered to possess a genetically stable genome; only one serotype is recognized around
the world. The 125-kbp genome contains ;70 open reading frames. One that has received particular attention is open
reading frame 68, which codes for glycoprotein gE, the predominant 623-residue viral envelope product that harbors both B
and T cell epitopes. This report describes the initial characterization of a community-acquired VZV isolate that was a
distinguishable second serotype (i.e., it had lost a major B cell epitope defined on the gE ectodomain by a murine monoclonal
antibody called mAb 3B3). The mAb 3B3 epitope was found not only on the prototype sequenced Dumas strain from Holland
and all previously tested North American isolates but also on the varicella vaccine Oka strain originally attenuated in Japan.
Sequencing of the mutated gE ectodomain demonstrated that codon 150 exhibited a single base change that led to an amino
acid change (aspartic acid to asparagine). Observation of the monolayers infected with the mutant VZV strain also led to the
surprising discovery that the topography of egress was altered. Wild-type VZV emerges along distinctive viral highways,
whereas the mutant strain virions were nearly uniformly distributed over the cell surface in a pattern more closely resembling
egress of herpes simplex virus 1. The mutant VZV strain was designated VZV-MSP because it was isolated in Minnesota.
© 1998 Academic Press
INTRODUCTION
Varicella-zoster virus (VZV) is an ancient virus. Esti-
mations of its origins have established that the mod-
ern herpesviruses arose ;60–80 million years ago
(McGeoch and Cook, 1994; McGeoch et al., 1995). VZV
is a member of the alphaherpesvirus subfamily of
Herpesviridae. It is the etiological agent of chickenpox
in childhood, after which the virus enters a latent state
in the dorsal root ganglia; decades later, the same
virus reactivates and causes the disease shingles
(herpes zoster). The entire sequence of the 125-kbp
VZV genome has been published by Davison and Scott
(1986). With the subsequent publication of sequence
data from other herpesviruses, the alphaherpesvi-
ruses have now been subdivided into two genera
called simplexvirus and varicellovirus (McGeoch and
Cook, 1994). VZV is considered to have one of the most
stable genomes of all herpesviruses. The Oka strain of
varicella vaccine that was derived from a Japanese
child with chickenpox has a few minor genomic differ-
ences from North American strains, but to date no
antigenic variation has been discovered among the
major surface immunogens of the virion (Arvin and
Gershon, 1996).
VZV gE is the predominant glycoprotein specified in in-
fected cells and virions; this fact is in marked distinction to
the related herpes simplex virus type 1 (HSV-1), in which gE
is a relatively minor constituent (Spear, 1985; Grose, 1990).
In both VZV and HSV-1 infections, gE is a biologically active
Fc receptor on the surface of infected cells. The VZV Fc
receptor is distinguished by the fact that it contains motifs
in its cytoplasmic tail that direct export from the endoplas-
mic reticulum, trafficking to the trans-Golgi network as well
as endocytosis from the outer cell membrane (Nishimura
and Balch, 1997; Zhu et al., 1995, 1996; Olson and Grose,
1997, 1998). The precise role of the VZV Fc receptor activity
remains to be elucidated, but the homolog gE is intimately
involved in cell-to-cell spread of other alphaherpesviruses
(Dingwell et al., 1994).
In VZV infection in humans, VZV gE is a major antigenic
determinant to which numerous humoral and cytolytic re-
sponses are observed (Ito et al., 1985; Arvin et al., 1986;
Bergen et al., 1991). Recently, an immunodominant B cell
epitope was demarcated in the gE ectodomain; the epitope
is defined by murine monoclonal antibody (mAb) 3B3 (Duus
and Grose, 1996; Hatfield et al., 1997). Because of the
widely accepted genetic stability of this herpesvirus, we
had assumed this epitope would be present in all VZV
isolates worldwide. In this report, we describe a communi-
ty-acquired VZV strain with an unexpected mutation in the
gE ectodomain that leads to the loss of an immunodomi-
nant B cell epitope. The mutant virus strain also exhibits an
alteration in the topography of egress.
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RESULTS
Analysis of the VZV isolate by confocal microscopy
The virus designated VZV-MSP was initially isolated in
human fibroblast monolayers. The cytopathic effect
(CPE) was compatible with VZV, but the isolate was
poorly reactive with antibodies in a commercial VZV
diagnostic kit. Because the isolate did not stain with
antibodies to HSV types 1 and 2 nor did its CPE resemble
that of HSV, the virus isolate was sent to our laboratory
for further analysis. When the isolate (VZV passage 1)
was received, the infected cell monolayer was trypsin-
dispersed and inoculated onto human melanoma cells
(VZV passage 2). When CPE was apparent in 5 days, the
infected cell monolayer was trypsin-dispersed one more
time and inoculated onto 35-mm monolayers for exami-
nation by laser scanning confocal microscopy (VZV pas-
sage 3). The low-passage VZV-32 strain was included in
separate dishes as a control virus. When CPE covered
;70% of each monolayer, the infected monolayers were
probed with mAb 3B3 against gE and with mAb 6B5
against gI and examined by confocal microscopy. In prior
studies, we showed that these two mAbs do not cross-
react with other viral or cellular proteins (Grose, 1990).
FIG. 1. Loss of mAb epitope 3B3 in the VZV-MSP strain. Low-passage laboratory strain VZV-32 (A and B) and community strain VZV-MSP (C and
D) were inoculated onto human melanoma cells. After 3 days, the cultures were probed with mAb 3B3 against gE (A and C) and mAb 6B5 against
gI (B and D). Nuclei are stained red and the viral glycoproteins are stained green when analyzed by laser scanning confocal microscopy. (C) Note
the absence of green staining of the mutant VZV-MSP strain.
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FIG. 4. Epitope mapping with mAb 3B3 in VZV gL. Individual monolayers were transfected with pTM1 plamids carrying VZV gL alone, gL 3B3.11,
and gL 3B3.13. The construction of the plasmids is described in Materials and Methods. The attachment of mAb 3B3 to VZV gL 3B3.11 (A) and VZV
gL 3B3.13 (B) was evaluated by laser scanning confocal microscopy. Monolayers transfected with VZV gL alone were nonreactive with mAb 3B3 (not
shown). (Magnification bars) 30 mm.
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As expected from numerous published experiments,
mAb 3B3 and mAb 6B5 reacted with the laboratory strain
VZV-32 (Fig. 1). In marked contrast, the anti-gE mAb 3B3
did not attach to cells infected with the VZV-MSP strain,
even though mAb 6B5 did bind the infected cells strongly
(Fig. 1). As an additional control, the anti-gH mAb 206
was added to cultures individually infected with both VZV
strains; all VZV-infected cultures were positive in this
assay (data not shown).
We next immediately addressed the question of
whether the VZV-MSP strain fails to express the entire
glycoprotein or has lost an epitope on the glycopro-
tein. In this quest, we were fortunate in that we had
begun epitope mapping of gE. Through this method-
ology, we established that the 3B3 epitope consisted
of at least 11 amino acids (151–161) of gE (Duus and
Grose, 1996). We also determined that our panel of
mAbs included reagents against other nonoverlapping
epitopes on gE; one of these antibodies, mAb 711,
attaches to another as-yet-undefined epitope on the
ectodomain of gE. Therefore, the above experiment
was repeated with mAb 711 as the immunoprobe of
VZV-32- and VZV-MSP-infected monolayers. Both
monolayers stained positively, a result that indicated
that gE was expressed in VZV-MSP-infected cells but
appeared to have lost either a small segment of its
ectodomain or just the 3B3 epitope (Fig. 2).
Sequence analysis of VZV-MSP gE
To further investigate the nature of the gE mutation, we
used polymerase chain reaction (PCR) amplification
techniques to first determine whether a full-length gE
gene (VZV ORF 68) was present in the mutant strain. We
were able to amplify a full-length gene of an appropriate
size. Thereafter, we substituted primers that amplified
overlapping portions of the gE gene, each ;300 bases in
size, beginning at the upstream region of ORF 68. Each
fragment was subjected to DNA sequencing, and each
sequence was compared with the published (Davison
and Scott, 1986) sequence of the Dumas strain (Fig. 3A;
accession No. X04370). After analysis of the first 337
codons of VZV-MSP gE ORF, we found the first and most
important base change in codon 150 (Fig. 3B, arrow); the
substitution involved a replacement of a guanine by an
adenine. Of great interest, this point mutation led to a
change in amino acid from aspartic acid to asparagine
(Fig. 3B). Because this alteration in gE occurred one
amino acid away from the deduced 3B3 epitope, which is
underlined in Fig. 3A, the sequence data strongly sug-
gested that amino acid 150 was a previously unrecog-
nized contributor to the 3B3 epitope. Further sequencing
of VZV-MSP gE revealed one silent mutation in codon
341 of VZV-MSP gE. All other codons were identical to
those in the gE sequence of the Dumas strain.
Epitope mapping of VZV-MSP gE
In an earlier experiment, we had evaluated the 3B3
epitope by inserting the 11-amino-acid sequence into the
unrelated VZV ORF 60, namely, the gL glycoprotein (Duus
and Grose, 1996). The epitope tag within gL was recog-
nized by mAb 3B3 when observed by laser scanning
confocal microscopy. To evaluate the contribution of the
aspartic acid residue to formation of the epitope, the gL
epitope mapping and tagging experiment was repeated
to insert the aspartic acid residue in its correct location
at the N terminus of the 3B3 epitope. To obtain the proper
parameters for the mutagenesis primers, one additional
codon was inserted along with an aspartic acid (Fig. 3B).
The pTM-1 expression plasmids, including gL-3B3.11 and
gL-3B3.13, were transfected into HeLa cells and ob-
served by confocal microscopy after labeling with mAb
3B3 (Fig. 4). Cells transfected with the gL-3B3.11 plasmid
were positive in a restricted cytoplasmic pattern, as
previously described by Duus and Grose (1996). Not only
were cells transfected with the gL-3B3.13 more intensely
stained, but also the pattern was more widely distributed
FIG. 2. Expression of VZV gE in wild-type and mutant VZV strains.
Individual monolayers were infected with the VZV-32 strain (A) and the
VZV-MSP strain (B). The monolayers were incubated with mAb 711 and
examined by laser scanning confocal microscopy on day 3 p.i. An
uninfected monolayer had a negative background (not shown).
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throughout the cytoplasm. Cells transfected with the
pTM-1 gL plasmid alone were negative.
Subcloning the VZV-MSP gE ORF
After completion of the above experiment, we
sought to confirm the epitope experiments by ampli-
fying the entire gE gene from VZV-MSP DNA and
inserting it into a pTM-1 expression vector. We had
previously cloned wild-type gE into the same expres-
sion vector; the same primers were used for the sec-
ond cloning experiment (Yao et al., 1993). After tran-
sient transfection with these two forms of VZV gE as
well as the pTM-1 vector as a control, the cell lysates
were solubilized and subjected to electrophoresis fol-
lowed by transfer to membranes. Additional control
samples for the transfection immunoblotting experi-
ments included MeWo cell monolayers infected with
three VZV strains: VZV-32, VZV-Oka, and VZV-MSP.
Uninfected MeWo cells served as a negative control.
All samples were blotted with mAb 3B3 followed by
chemiluminescence (Fig. 5). The mAb attached to VZV-
32, VZV-Oka, and VZV gE wild-type but not to VZV-MSP,
VZV-MSP gE, or the vector and uninfected cell con-
trols. When VZV-MSP gE was subsequently immuno-
blotted with a polyclonal monospecific antibody to gE,
the result was positive. Thus, the results in Figure 5
confirmed that VZV-MSP gE by itself was expressed
but lacked the 3B3 epitope.
Alterations in topography of egress of viral particles
In previously published studies, we documented that
the egress of wild-type VZV particles onto the surface of
infected cells occurs in a distinctive pattern that was
termed “viral highways” (Harson and Grose, 1995). The
viral highways are composed of thousands of viral par-
ticles that emerge in long rows across the surface of the
syncytia. When the distributions of VZV-32 and VZV-MSP
particles were compared at a low-magnification level by
scanning electron microscopy (SEM), wild-type virions
were again arranged in a pattern consistent with viral
highways (Figs. 6A–6C). Cells infected with the VZV-Oka
strain show a similar pattern of viral highways (Grose,
1996). In contrast, no such topographical pattern was
observed on samples infected with VZV-MSP; instead,
viral particles were distributed more uniformly over the
cell surface (Figs. 6D–6F). After the observation of nu-
merous monolayers by SEM, the viewer was left with the
impression that the number of VZV wild-type virions
present on the cell surface was less than those of VZV-
MSP (compare Figs. 6C and 6F). The topographical ar-
rangement of VZV-MSP particles also exhibited a high
FIG. 3. Sequence of the ectodomain of VZV gE. (A) The deduced amino acid sequence of the N-terminal 400 of 623 codons of wild-type VZV gE.
(Underlined) Previously defined mAb 3B3 epitope. (Arrowhead at codon 150) The aspartic acid residue altered in VZV-MSP. (Arrowhead at codon 341)
The silent mutation. (B) DNA and deduced amino acid sequence of the mAb 3B3 epitope in the wild-type VZV-32 strain and the mutant VZV-MSP strain.
(Underlined and arrows) The altered nucleotides (G–A) and amino acids (D–N). The two additional codons inserted into the expression plasmid
described in Figure 4 are designated 3B3.2, and the original 3B3 epitope is designated 3B3.11. (See Materials and Methods.)
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degree of similarity with that of HSV-1, in which thou-
sands of particles covered the cell surface (Fig. 7).
The observation that CPE in a VZV-infected monolayer
follows the longitudinal axis of the cells in the monolayer
was first made by Weller (1953). In VZV-infected human
melanoma cell cultures, individual syncytial foci enlarge
and eventually merge until the entire monolayer has
become a single syncytium. Virions emerge only after
syncytia are formed, but the virions are never released
into the culture medium. If syncytial formation is blocked
by the addition of anti-gH antibody into the culture me-
dium, virions do not egress until the antibody is removed
(Rodriguez et al., 1993). Based on the imaging studies in
this as well as previous reports, we postulate that virions
exit at the leading edge of syncytial foci that are merging.
We further postulate that VZV egress (gE/gI mediated)
and VZV-induced cell-to-cell fusion (gH/gL mediated) are
separate but interdependent events. The mutation on
VZV-MSP gE appears to lessen that interdependence.
DISCUSSION
Among the human herpesviruses, VZV has always
been considered to have a very stable genome (Rentier,
1995). Generally, one serotype is recognized around the
world. There are some minor differences noticed by
restriction-fragment-length-polymorphism analyses be-
tween Japanese VZV strains and VZV strains from North
America, but these genetic changes have never been
correlated with changes in specific epitopes (LaRussa et
al., 1992). A geographic-specific sequence variation in
the ORF 10 late gene product between Japanese and
North American strains has been described by Kinching-
ton and Turse (1995). They prepared an antibody directed
against a synthetic peptide consisting of the N-terminal
14 amino acids of the Dumas strain of ORF 10. The
antibody bound to 10 VZV isolates collected in the United
States but failed to bind to 10 VZV isolates obtained in
Japan. Whether this 14-mer represents a B cell epitope to
which the VZV-infected human host usually manifests an
immune response was not determined in the above
study, but it seems unlikely because ORF 10 is not
present on the surface of the virion. More likely, the ORF
10 sequence variant represents a VZV equivalent of the
“founder effect,” in which a human genetic disease
emerges within one ethnic group or a geographically
isolated population.
The 3B3 epitope within the gE ectodomain is easily
detectable by immunoelectron microscopy on the sur-
face of the enveloped virion (Jones and Grose, 1988).
Based on both published and unpublished data accumu-
lated after the initial characterization of mAb 3B3, the 3B3
epitope has been detected on all wild-type North Amer-
ican isolates examined in this laboratory since 1983
(Grose et al., 1983; Weigle and Grose, 1983). The epitope
as defined in this report is present in the sequence of the
prototype VZV strain analyzed by Davison and Scott
FIG. 5. Immunoblotting of VZV strains and gene products. An immunoblot was prepared with each of the following lysates as antigens: melanoma
cells alone (lane 1), wild-type gE alone (lanes 2, 7, and 10), VZV-32 strain-infected cells (lane 3), VZV-Oka-infected cells (lane 4), VZV-MSP-infected cells
(lane 5), vaccinia virus alone (lanes 6 and 9), and mutant VZV-MSP gE alone (lanes 8 and 11). Lanes 1–8 were probed with mAb 3B3, and lanes 9–11
were incubated with a rabbit polyclonal monospecific anti-gE antibody (Rab 2).
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(1986); based on both results in Figure 5 and gE se-
quence data provided by the Merck Company (A. Shaw,
unpublished data), the same epitope is present in the
Oka varicella vaccine strain originating in and represen-
tative of VZV strains from Japan. The fact that our initial
epitope tagging experiments were successful without
the N-terminal aspartic acid suggests that by chance, the
amino acids in the gL ORF immediately N terminal to the
inserted 3B3 epitope partially compensated for the ab-
sent aspartic acid in the epitope. When an aspartic acid
was inserted into the epitope tag on gL and the imaging
experiment was repeated, the intensity of staining by
FIG. 6. Topography of egress of VZV particles at three magnifications. (A–C) Surface of VZV-32 wild-type syncytium with emergent virions distributed
in viral highways. (D–F) Surface of VZV-MSP syncytium with emergent virions distributed in a more uniform pattern. (Magnification bars) A and D, 20
mm; B and E, 2 mm; and C and F, 1 mm.
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mAb 3B3 under confocal microscopic visualization was
increased severalfold.
The alteration in the VZV gE epitope from a community
isolate resembles antigenic drift in influenza A virus; that
is, a single base change within an epitope leads to a
single amino acid change, which in turn leads to the loss
of an epitope on the major cell surface hemagglutinin
(HA) molecule (Wharton et al., 1989; Smith and Palese,
1989). Generally, these genetic changes in influenza vi-
rus are restricted to sites on the HA1 domain of the HA
molecule, usually on a loop. The HA1 nucleotide muta-
tion rate has been estimated at 0.0067 substitution per
FIG. 7. Topography of egress of HSV-1 particles. A low-magnification SEM of HSV-1 virions over the cell surface resembles the pattern seen with
VZV-MSP strain (Figs. 6D–6F). (Magnification bar) 1 mm.
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site per year. Clustering of the substitutions within a few
sites suggests the influence of immune pressure. One
such HA1 change is identical to that seen in VZV gE,
namely, a switch from an aspartic acid to an asparagine
residue. The silent nucleotide substitution rate for other
influenza virus genes is lower and ranges from 0.0018 to
0.0031 substitution per site per year. Even though anti-
genic drift is a less drastic change than antigenic shift, it
leads to sufficient antigenic change to allow escape from
immunological surveillance by existing antibodies in the
host. We note that the asparagine mutation in VZV gE
does not specify a new potential site of N-linked glyco-
sylation.
In addition to influenza A virus, mutation rates have
been tabulated for human immunodeficiency virus type 1
(HIV-1) (Hahn et al., 1986). The nucleotide substitution
rate for the HIV-1 envelope gene is estimated to be at
least 0.001 per site per year, whereas that of the gag
gene is less common. One site of variability in the HIV
glycoprotein ORF is concentrated within or adjacent to
the immunodominant V3 loop of the HIV-1 glycoprotein
(Shioda et al., 1992). The mutation rates for eukaryotic
DNA genomes have been estimated to be ;1 million
times lower, ;1029 nucleotide substitutions per site per
year (Holland et al., 1982; Gojobori and Yokoyama, 1985).
After extensive sequence analysis of five herpesviral
genes by means of both maximum parsimony and dis-
tance methods, McGeoch et al. (1995) determined that
VZV and other alphaherpesviruses exhibit a nucleotide
substitution rate between 10 and 100 times faster than
that of eukaryotic DNA (1027 to 1028 changes per site
per year) but still much slower than that of many RNA or
retroviruses.
Antigenic variation of a VZV surface protein may have
implications for our understanding of the pathogenesis
of VZV infection. The preponderance of opinion today is
that T cell-mediated immunity is crucial for the eradica-
tion of primary viral infection (Arvin and Gershon, 1996;
Grose, 1998). However, the loss of a B cell epitope on an
immunodominant VZV glycoprotein raises the question
of whether antibody modulates an early event in VZV
pathogenesis, probably cell-to-cell spread and virion
egress mediated by gE. One potential mechanism for
selective pressure involves a newly described T cell-
independent antibody-mediated clearance of virus (Szo-
molanyi-Tsuda and Welch, 1996). In the polyomavirus
mouse model, there is a lethal infection in severe-
combined-immunodeficiency mice, whereas in nude
mice, a rapid fully protective predominantly IgG antiviral
response is produced without any T cell assistance. The
polyomavirus antigen is a viral capsid with a major gly-
coprotein that is repeated 360 times in 72 pentameters.
The authors speculate that the structural periodicity of
the viral capsid antigen may induce a T cell-independent
antibody response. This concept expands on earlier ob-
servations from the Zinkernagel laboratory that B cells
are weakly responsive to the vesicular stomatitis virus
glycoprotein when presented in a poorly organized pat-
tern on a cell surface but are strongly responsive to the
same viral glycoprotein antigen when presented in a
highly organized repetitive pattern on the virion surface
(Bachman et al., 1993). Similarly, a VZV-specific early T
cell-independent antibody response directed against gE
on a capsid would explain a selective pressure favoring
replication of a mutant virus lacking an immunodominant
B cell epitope. Studies are currently under way to enu-
merate the precise number of gE molecules detectable
in the emergent VZV envelopes.
MATERIALS AND METHODS
Viruses and cells
The mutant VZV was isolated from a 6-year-old boy
with leukemia who contracted chickenpox and was hos-
pitalized for intravenous acyclovir treatment in late 1995.
The child’s illness responded to treatment, and no un-
usual sequelae were observed. The child’s vesicle fluid
was inoculated onto MRC-5 cells in glass tubes, which
were commercially purchased. The isolate was desig-
nated VZV-MSP because the child lived in Minnesota.
The VZV-32 laboratory strain was isolated in Texas in
1976 from an otherwise healthy child with chickenpox
(Grose, 1980). This virus has never been passaged .20
times. The VZV-Oka strain was isolated from a Japanese
child with chickenpox and attenuated by M. Takahashi in
Japan in the 1970s (Takahashi et al., 1975). All viruses
were subcultured in either MRC-5 cells or human mela-
noma cells (MeWo strain). MeWo cells are highly permis-
sive for VZV replication, but no infectious virus is re-
leased into the culture medium (Grose, 1980). Therefore,
transfer of infectivity is carried out by trypsin dispersion
of infected cells and relayering of infected cells onto an
uninfected monolayer at a ratio of 1:8 (infected-to-unin-
fected cells). The HSV-1 Miyama strain was propagated
in the FL line derived from human amnion cells (Padilla
et al., 1997).
Antibodies and immunodetection by confocal
microscopy
mAb 3B3 was produced in this laboratory in 1983
(Grose et al., 1983). The antigen for mouse immunization
was VZV-32-infected cells. mAb 3B3 attaches to VZV gE
even under the stringent condition of a buffer containing
1% SDS. Other mAbs to VZV gE (mAb 711), VZV gI (mAb
6B5), and VZV gH (mAb 206) were also produced and
characterized in this laboratory. Conditions for immuno-
detection of VZV proteins by laser scanning confocal
microscopy have been outlined by Duus and Grose,
1996. Immunoblotting was performed with the above
antibodies as described (Grose, 1990).
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Epitope mapping by recombination PCR mutagenesis
The technique of recombination PCR mutagenesis
has been adapted to investigate epitope mapping and
tagging (Yao et al., 1993; Hatfield et al., 1997). By this
methodology, the epitope of mAb 3B3 was initially
defined between amino acids 151–161 in the ectodo-
main of the 623-amino-acid gE glycoprotein. The meth-
odology for producing plasmid pTM1-VZV gL 3B3.11 is
described in detail by Hatfield et al. (1997). As part of
the investigation in Results (Fig. 8), an additional two
codons were inserted at the N terminus of the 11-
amino-acid 3B3 epitope to produce a 13-amino-acid
epitope tag in the VZV gL protein. The mutating prim-
ers included MP23 (sense) (CAT ACT GTG TCG ACC
AAA GGC AAT ACG GTG ACG TG) and MP24 (anti-
sense) (TTG CCT TTG GTC GAC ACA GTA TGC GAT
TGT GAT AG). PCR amplification was performed under
the following parameters: 94°C denaturation for 30 s,
50°C annealing for 30 s, and 72°C extension for 5 min;
after 25 cycles, there was a final extension at 72°C for
7 min. PCR products were combined and transformed
into cells in which the overlapping regions underwent
recombination to yield a plasmid containing the mu-
tagenized insert. Plasmid purification was performed
with a Qiagen Maxi Kit. The newly designated pTM1-
VZV gL 3B3.13 plasmid was partially sequenced at the
University of Iowa DNA Core Facility to confirm the
authenticity of the insertional mutagenesis. This PCR
mutagenesis protocol is very reliable with a error
frequency of ,0.025% (Jones and Howard, 1990).
Subcloning of VZV-MSP gE
The subcloning of wild-type VZV gE has been de-
scribed previously (Yao et al., 1993). Briefly, two flanking
PCR primers were used that amplified the VZV-MSP gE
ORF directly from VZV-MSP-infected melanoma cells.
These primers also created a SacI and a SpeI restriction
enzyme site at the 59- and 39-ends, respectively. The
primers were Nco gpI (sense) (CGA CCC GGG GAG CTC
CCA TGG GGA CAG TTA ATA AAC C) and IP2 (antisense)
(CGC TCT AGA ACT AGT GGA TCC CCC GGG GAA TTT
GTC ACA GGC TTT T). PCR amplification was performed
under the following conditions: 94°C denaturation for
40 s, 50°C annealing for 40 s, and 72°C extension for 4
min; after 35 cycles, there was a final extension at 72°C
for 7 min. After amplification, the PCR fragment was
digested with SacI and SpeI before cloning into the
multiple cloning site of the expression vector pTM1.
Imaging of viral particles
Clean coverslips were coated with carbon, hydrophi-
lized, and irradiated with UV light for 12 h, followed by a
glow discharge for a few seconds and then sterilization
by dry heat (160°C overnight). MeWo cells were culti-
vated on the glass coverslips. When the cells became
confluent, they were cocultivated with either VZV-32- or
VZV-MSP-infected cells at a 1:8 ratio and incubated at
32°C. At the designated times after infection, the cells
were prefixed with 1% glutaradehyde in phosphate-buff-
ered saline (PBS) at 4°C for 1 h, rinsed in chilled PBS
followed by postfixation with 1% osmium tetraoxide in
PBS at 4°C for 1 h, and then dehydrated in a graded
ethanol series. Finally, after two changes in 100% etha-
nol, the specimens were subjected to a critical point
drying method. In the case of HSV-1 samples, FL cells
prepared on coverslips were inoculated with HSV-1
Miyama strain at an m.o.i. of 10. At 24 h after virus
inoculation, coverslips were washed with PBS and pro-
cessed as described for VZV. Subsequently, the speci-
mens were mounted onto aluminum plates and observed
with either an Hitachi S-4000 or an Hitachi S-900 SEM.
Imaging was performed at the University of Iowa Central
Microscopy Research Facility and the University of Wis-
consin-Madison Integrated Microscopy Facility.
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